JP2014527979A - 増殖性疾患を治療するためのストリゴラクトンおよびストリゴラクトンアナログの使用 - Google Patents

増殖性疾患を治療するためのストリゴラクトンおよびストリゴラクトンアナログの使用 Download PDF

Info

Publication number
JP2014527979A
JP2014527979A JP2014531375A JP2014531375A JP2014527979A JP 2014527979 A JP2014527979 A JP 2014527979A JP 2014531375 A JP2014531375 A JP 2014531375A JP 2014531375 A JP2014531375 A JP 2014531375A JP 2014527979 A JP2014527979 A JP 2014527979A
Authority
JP
Japan
Prior art keywords
methyl
cells
strigolactone
dihydro
dihydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531375A
Other languages
English (en)
Japanese (ja)
Inventor
カプルニク，ヨラム
コルタイ，ヒナニット
ヤーデン，ロニット
プランディ，クリスティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JP2014527979A publication Critical patent/JP2014527979A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014531375A 2011-09-21 2012-09-20 増殖性疾患を治療するためのストリゴラクトンおよびストリゴラクトンアナログの使用 Pending JP2014527979A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161537062P 2011-09-21 2011-09-21
US61/537,062 2011-09-21
US201261614965P 2012-03-23 2012-03-23
US61/614,965 2012-03-23
PCT/IL2012/050381 WO2013042124A1 (en) 2011-09-21 2012-09-20 Use of strigolactones and strigolactone analogs for treating proliferative conditions

Publications (1)

Publication Number Publication Date
JP2014527979A true JP2014527979A (ja) 2014-10-23

Family

ID=47913975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531375A Pending JP2014527979A (ja) 2011-09-21 2012-09-20 増殖性疾患を治療するためのストリゴラクトンおよびストリゴラクトンアナログの使用

Country Status (7)

Country Link
US (1) US10208007B2 (cg-RX-API-DMAC7.html)
EP (1) EP2758392B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014527979A (cg-RX-API-DMAC7.html)
CN (1) CN104053655A (cg-RX-API-DMAC7.html)
CA (1) CA2849343C (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02680A (cg-RX-API-DMAC7.html)
WO (1) WO2013042124A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458154B2 (en) 2013-09-06 2022-10-04 Vanda Pharmaceuticals Inc. Treatment of CYR61- and VEGF-mediated conditions
US20180235213A1 (en) * 2015-05-14 2018-08-23 The State of Israel Ministry of Agriculture & Rural Develop. Agricultural Research Organization Plant hormone application
GB201615544D0 (en) * 2016-09-13 2016-10-26 Syngenta Participations Ag Plant Growth regulator compounds
CN108558796B (zh) * 2018-05-07 2020-04-07 南开大学 一类羟亚甲基氢化茚酮衍生物及其制备方法和用途
CN108675974B (zh) * 2018-05-07 2020-04-07 南开大学 一类独脚金内酯衍生物及其制备方法和用途
EP3876927A1 (en) * 2018-11-08 2021-09-15 Universita' Degli Studi di Torino Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family
CN117843651B (zh) * 2024-01-03 2024-09-10 盐城工学院 一种含有三氟甲基季碳中心的四氢呋喃并[3,2-b]吲哚啉类化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077177A2 (fr) * 2004-02-10 2005-08-25 Universite Paul Sabatier Toulouse Iii Modulateurs de developpement des champignons mycorhiziens a arbuscules, et applications
JP2010529975A (ja) * 2007-06-15 2010-09-02 バイエル・クロツプサイエンス・エス・アー ストリゴラクトン誘導体と殺菌剤化合物を含んでいる殺有害生物剤組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904331A (en) 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and an insecticide compound
EP2248421A1 (en) 2009-05-07 2010-11-10 GMI - Gregor-Mendel-Institut für Molekulare Pflanzenbiologie GmbH Accumulation of biomass in plants
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077177A2 (fr) * 2004-02-10 2005-08-25 Universite Paul Sabatier Toulouse Iii Modulateurs de developpement des champignons mycorhiziens a arbuscules, et applications
JP2010529975A (ja) * 2007-06-15 2010-09-02 バイエル・クロツプサイエンス・エス・アー ストリゴラクトン誘導体と殺菌剤化合物を含んでいる殺有害生物剤組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6016018937; Ｅｕｒ．　Ｊ．　Ｏｒｇ．　Ｃｈｅｍ，　２０１１　Ｊｕｌ，　Ｖｏｌ．２０１１，　ｐ．３７８１-３７９３ *
JPN6016018941; ＡＣＳ　Ｓｙｍｐ．　ｓｅｒ．，　１９９１，　Ｖｏｌ．４４３，　ｐ．２７８-２８７ *
JPN6016018944; Ｊ．Ｃ．Ｓ．　Ｃｈｅｍ．　Ｃｏｍｍ．，　１９７４，　Ｖｏｌ．１３，　ｐ．５１２-５１３ *

Also Published As

Publication number Publication date
CA2849343A1 (en) 2013-03-28
CN104053655A (zh) 2014-09-17
US10208007B2 (en) 2019-02-19
EP2758392B1 (en) 2019-09-18
EP2758392A4 (en) 2015-05-20
EP2758392A1 (en) 2014-07-30
US20140323563A1 (en) 2014-10-30
CA2849343C (en) 2020-12-15
WO2013042124A8 (en) 2013-07-25
WO2013042124A1 (en) 2013-03-28
IN2014CN02680A (cg-RX-API-DMAC7.html) 2015-07-03

Similar Documents

Publication Publication Date Title
JP2014527979A (ja) 増殖性疾患を治療するためのストリゴラクトンおよびストリゴラクトンアナログの使用
Qiang et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study
Lee et al. α‐Mangostin, a novel dietary xanthone, suppresses TPA‐mediated MMP‐2 and MMP‐9 expressions through the ERK signaling pathway in MCF‐7 human breast adenocarcinoma cells
US10238631B2 (en) Sesquiterpene derivatives and their use in inflammation or cancer treatment
Cui et al. Neuroprotective effect of sulfated polysaccharide isolated from sea cucumber Stichopus japonicus on 6-OHDA-induced death in SH-SY5Y through inhibition of MAPK and NF-κB and activation of PI3K/Akt signaling pathways
Lee et al. Arctigenin shows preferential cytotoxicity to acidity-tolerant prostate carcinoma PC-3 cells through ROS-mediated mitochondrial damage and the inhibition of PI3K/Akt/mTOR pathway
Wu et al. Berberine inhibits the proliferation of human uterine leiomyoma cells
Liu et al. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-κB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways
Xia et al. Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line
Shan et al. First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway
Zhang et al. Isocryptotanshinone induced apoptosis and activated MAPK signaling in human breast cancer MCF-7 cells
Liou et al. Calebin-A induces cell cycle arrest in human colon cancer cells and xenografts in nude mice
US20250381166A1 (en) Cannabis-Derived Flavonoids And Related Methods
JPWO2008139952A1 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
ITRM20130502A1 (it) Estratto di filipendula vulgaris e suoi usi
US20170340688A1 (en) Titrated extracts of cynara scolymus and uses thereof
TWI542348B (zh) 含４－乙醯基－安卓奎諾－ｂ之組合物用於製備抑制癌細胞生長之藥物的用途
Zhu et al. Deacetyl-mycoepoxydiene, isolated from plant endophytic fungi Phomosis sp. demonstrates anti-microtubule activity in MCF-7 cells
Wang Dietary Compound Diosmetin Chemosensitizes Breast Cancer Stem Cells by Suppressing HMGB1-mediated Autophagy
KR101547885B1 (ko) Ｓｉｒｔ７ 단백질의 탈아세틸화 활성을 저해하는 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
KR101596276B1 (ko) Ｓｉｒｔ７ 단백질의 탈아세틸화 활성을 저해하는 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
Bozóki-Nové Efflux pump inhibitors and potential adjuvants to reverse multidrug resistance in bacteria and tumor cells
Liu et al. Spatholobus suberectus Dunn inhibits breast cancer bone metastasis in vitro and in vivo
US20150231090A1 (en) Usage of guttiferone k for treating high metastatic cancer
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170110